US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Dame Judi Dench's tears as she receives Sycamore Gap tree seedling at Chelsea Flower Show
Dame Judi Dench shed a tear yesterday after being presented with a seedling from the famous Sycamore2024-05-22Hilarious moment Moto3 rider accidentally jumps onto a rival's bike mid
This is the incredible moment Moto3 Americas GP racer Ivan Ortola climbed onto the WRONG motorbike f2024-05-22National cultural parks enshrining Chinese ethos
BEIJING, Oct. 13 (Xinhua) -- Every weekend, Yang Jie spends at least a morning at a book house by th2024-05-22New rules for Pregnant Workers Fairness Act include divisive accommodations for abortion
NEW YORK (AP) — Workers are entitled to time off and other job accommodations for abortions — along2024-05-22Bichette has 4 hits, Berríos snaps 4
TORONTO (AP) — Bo Bichette had three doubles among his four hits, José Berríos pitched six solid inn2024-05-22- Fans are raving about the new Netflix show Baby Reindeer, but many are questioning the real identity2024-05-22
atest comment